Evidence map›Paper›PMID 33426736›Full record

Observational studyCancer science2021

Serum exosomal miR-638 is a prognostic marker of HCC via downregulation of VE-cadherin and ZO-1 of endothelial cells.

Yuki Yokota, Takehiro Noda, Yuichiro Okumura, Shogo Kobayashi, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Hirofumi Akita, Kunihito Gotoh, Yutaka Takeda and 5 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Yuki YokotaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Takehiro NodaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.ORCID https://orcid.org/0000-0002-6768-5783
Yuichiro OkumuraDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Shogo KobayashiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.ORCID https://orcid.org/0000-0002-8828-1067
Yoshifumi IwagamiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Daisaku YamadaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.ORCID https://orcid.org/0000-0002-6702-3800
Yoshito TomimaruDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Hirofumi AkitaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Kunihito GotohDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Yutaka TakedaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Masahiro TanemuraDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Takashi MurakamiDepartment of Microbiology, Saitama Medical University, Iruma, Japan.
Koji UmeshitaDivision of Health Science, Graduate School of Medicine, Osaka University, Suita, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.ORCID https://orcid.org/0000-0002-2318-1129
The University of Osaka · JPKansai Rosai Hospital · JPSaitama Medical University · JP

Funding

Scientific Research of the Japan Society for the Promotion of Science (C) 19K09146the SGH foundation
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death. High recurrence rates after curative resection and the lack of specific biomarkers for intrahepatic metastases are major clinical problems. Recently, exosomal microRNAs (miRNAs) have been reported to have a role in the formation of the pre-metastatic niche and as promising biomarkers in patients with malignancy. Here we aimed to clarify the molecular mechanisms of intrahepatic metastasis and to identify a novel biomarker miRNA in patients with HCC. A highly intrahepatic metastatic cell line (HuH-7M) was established by in vivo selection. HuH-7M showed increased proliferative ability and suppression of apoptosis and anoikis. HuH-7M and the parental cell (HuH-7P) showed the similar expression of epithelial-mesenchymal transition markers and cancer stem cell markers. In vivo, mice treated with exosomes derived from HuH-7M showed increased tumorigenesis of liver metastases. Exosomes from HuH-7M downregulated endothelial cell expression of vascular endothelial-cadherin (VE-cadherin) and zonula occludens-1 (ZO-1) in non-cancerous regions of liver and increased the permeability of FITC-dextran through the monolayer of endothelial cells. The miRNAs (miR-638, miR-663a, miR-3648, and miR-4258) could attenuate endothelial junction integrity by inhibiting VE-cadherin and ZO-1 expression. In patients with HCC, higher serum exosomal miR-638 expression was associated with tumor recurrence. In conclusion, the miRNAs secreted from a highly metastatic cancer cell can promote vascular permeability via downregulation of endothelial expression of VE-cadherin and ZO-1. Serum exosomal miR-638 expression holds potential for serving as a significant and independent prognostic marker in HCC.

Indexed as

AgedAged, 80 and overAnimalsAntigens, CDBiomarkers, TumorCadherin 5CadherinsCarcinoma, HepatocellularCell Line, TumorCell ProliferationDown-RegulationEndothelial CellsEpithelial-Mesenchymal TransitionExosomesFemaleGene Expression Regulation, NeoplasticAntigens, CDBiomarkers, TumorCadherin 5CadherinsMicroRNAsMIRN638 microRNA, humanTJP1 protein, humanZonula Occludens-1 Proteinexosomehepatectomyin vivo selectionliver cancermicroRNA

Identifiers

PMID33426736
PMCPMC7935782
OpenAlexW3119979905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.